Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors
Chief Operating Officer Jeff Hackman Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia , July 03, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN) today announced that Mark Corrigan , M.D. has been appointed as Executive Chair of the Board of
View HTML
Toggle Summary Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic disorder (HMD) by year-end VANCOUVER, British Columbia , June 25, 2018 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy VANCOUVER, British Columbia , June 01, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing
View HTML
Toggle Summary Novelion Therapeutics Reports First Quarter 2018 Financial Results
VANCOUVER, B.C. , May 10, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases ("Novelion" or the "Company"), today reported financial results for the first
View HTML
Toggle Summary Novelion Therapeutics Supports World Lipodystrophy Day
VANCOUVER, British Columbia , March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today recognizes World Lipodystrophy Day.
View HTML
Toggle Summary Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Novelion reports 2017 total net revenues of $138.4 million , in line with previously stated guidance Plans underway to address capital structure and advance metreleptin development program VANCOUVER, British Columbia , March 15, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.
View HTML
Toggle Summary Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
View HTML
Toggle Summary Novelion Therapeutics Observes Rare Disease Day
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases
View HTML
Toggle Summary Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals
Financial terms of the sentence align with previous company filings
View HTML
Toggle Summary Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review
Significant operating cost and workforce reductions estimated to lower operational expenses by approximately $18 million in 2018
View HTML